Targeted delivery of CD39 to ischaemic brain improves outcomes in stroke

将 CD39 靶向递送至缺血性大脑可改善中风的预后

• 批准号: nhmrc : GNT1141046
• 负责人: Prof Harshal Nandurkar
• 金额: $ 89.58万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeted-delivery-cd39-outcomes-stroke/1348346
• 关键词: Targeted; delivery; CD39; ischaemic; brain

Stroke is most likely caused by a clot in one of the large blood vessels supplying the brain. The approach is to save the 'at-risk' area of brain with drugs that break-down clots and by manual removal of clots. These treatments are limited by timely access within 4.5 hours to larger hospitals. We are trialing a new drug that protects the brain better on its own and may add to the benefit of current treatments. Moreover, it can be given in any rural setting.

中风最有可能是由供应大脑的大血管中的一个凝块引起的。该方法是通过药物分解血块和人工去除血块来挽救大脑的“危险”区域。这些治疗受到较大医院在4.5小时内及时获得治疗的限制。我们正在试验一种新药，它可以更好地保护大脑，并可能增加目前治疗方法的益处。此外，它可以在任何农村环境中进行。